ASX:CSL 16 February 2026 - 11 June 2026

CSL jumps 5.75% before ASX to restart after King’s Birthday break
·

CSL Shares Push Higher as Investors Revisit Turnaround After Writedowns

CSL shares closed at A$107.51 Friday, up 0.26%, trailing the S&P/ASX 200’s 1.98% gain. The stock extended its rebound to six sessions after a sharp fall triggered by a May 11 earnings downgrade. CSL flagged US$5 billion in further non-cash impairments for FY26–27. Analyst ratings remain mixed, with price targets ranging from A$108 to A$158.
June 12, 2026
CSL jumps 5.75% before ASX to restart after King’s Birthday break
·

CSL Shares Spike 4% With ASX Health Stocks Recovering

CSL shares jumped 4.16% to close at A$107.23 Thursday, outperforming the S&P/ASX 200, which fell 0.23%. About 2.8 million CSL shares changed hands, above average volume. The stock remains well below its 52-week high after recent guidance cuts and impairment warnings. No new operating update was issued Thursday.
June 11, 2026
CSL jumps 5.75% before ASX to restart after King’s Birthday break
·

CSL Shares Bounce Over $100 as Investors Watch for Bottom After Downgrade

CSL shares closed at A$102.95 in Sydney, up 3.5% from Tuesday, as investors moved into defensive healthcare stocks. The company issued no new operating update, with its last ASX filing on June 9 covering lapsed rights. CSL remains down 42.67% for 2026 after May’s profit warning. The S&P/ASX 200 rose 0.57% Wednesday, with healthcare up 0.88%.
June 10, 2026
CSL Shares Rise as ASX Sags: Why the A$100 Line Is Back in Focus
·

CSL Shares Rise as ASX Sags: Why the A$100 Line Is Back in Focus

CSL Ltd shares closed up 1.59% at A$99.47 on Tuesday, outperforming a weaker Australian market after the King’s Birthday holiday. The S&P/ASX 200 fell 0.24% as losses in mining and materials weighed. CSL’s move came without new company news, and the stock remains below A$100 after May’s profit warning and US$5 billion in flagged impairments. Analyst ratings on CSL remain mixed.
June 9, 2026
CSL jumps 5.75% before ASX to restart after King’s Birthday break
·

CSL jumps 5.75% before ASX to restart after King’s Birthday break

CSL Limited will resume ASX trading Tuesday after shares surged 5.75% to A$97.91 on Friday, outpacing a 0.7% drop in the S&P/ASX 200. The market was closed Monday for the King’s Birthday holiday. CSL remains down 59.29% for the financial year and recently cut FY26 guidance, warning of US$5 billion in impairments. Investors await the next move as trading resumes.
June 8, 2026
ASX Opens as Banks, Miners and Oil on Radar for Next Moves
·········

ASX Opens as Banks, Miners and Oil on Radar for Next Moves

The S&P/ASX 200 fell 0.7% to 8,625.10 on Friday, with BHP, Rio Tinto, and Fortescue all down as iron ore futures dropped for a fourth week. The market was closed Monday for the King’s Birthday holiday and is set for a cautious open Tuesday. Oil prices stayed high, while U.S. tech stocks rebounded during Australia’s break. The RBA cash rate remains at 4.35% ahead of the June 16 decision.
June 8, 2026
Cochlear Jumps; Eyes on Tuesday ASX Reopen After Pop
··

Cochlear Jumps; Eyes on Tuesday ASX Reopen After Pop

Cochlear shares closed at A$100.45 Friday, up 5.63%, but remain down 69% from last year’s high after an April profit warning slashed guidance. The S&P/ASX 200 fell 0.7% as markets head into the King’s Birthday holiday. Cochlear cited weak implant demand and hospital constraints. The next trading session opens Tuesday.
June 7, 2026
CSL Shares Up 5.75%, What Comes Next May Be Tougher
·

CSL Shares Up 5.75%, What Comes Next May Be Tougher

CSL Limited shares jumped 5.75% to A$97.91 on Friday, leading health care gains on the S&P/ASX 200 ahead of the King’s Birthday holiday. The rally followed a volatile week and a May downgrade, with CSL warning of US$5 billion in non-cash impairments and forecasting about US$3.1 billion net profit after tax. The ASX is closed Monday. Full-year results are due August 18.
June 7, 2026
ASX Faces Volatile Tuesday Reopen After Long Weekend as Banks and Miners Watch Wall Street
········

ASX Faces Volatile Tuesday Reopen After Long Weekend as Banks and Miners Watch Wall Street

The S&P/ASX 200 fell 0.7% to 8,625.10 on Friday, closing the week down 1.2% as banks and miners dragged the index lower. BHP, Rio Tinto, and Fortescue all declined alongside iron ore futures, while healthcare stocks rose. ASX trading resumes Tuesday after the King’s Birthday holiday. Megaport announced four AI infrastructure deals worth A$458.9 million and an A$827.3 million equity raising.
June 6, 2026
CSL Rises, $5 Billion Cloud Remains
····

CSL Rises, $5 Billion Cloud Remains

CSL Ltd shares closed up 2.57% at A$98.69 on Tuesday, recovering some ground after last week’s earnings reset, but remained 17.7% below their May 8 close. The company faces about $5 billion in additional non-cash impairments over FY26–27, following guidance cuts and asset write-downs. No new trading updates were issued Tuesday. Broader healthcare stocks also rose as the S&P/ASX 200 gained 1.17%.
May 19, 2026
CSL shares fall under A$100 with market wary on turnaround
····

CSL shares fall under A$100 with market wary on turnaround

CSL Ltd shares closed down 1.78% at A$96.22 on Monday, extending losses after last week’s profit downgrade and planned impairments. The stock is now nearly 20% below its May 11 level. CSL expects about $5 billion in additional non-cash, pre-tax impairments over FY26 and FY27. The company cited weaker U.S. and China sales, Middle East conflict, and increased competition as key pressures.
May 18, 2026
CSL shares under pressure as traders eye critical week
····

CSL shares under pressure as traders eye critical week

CSL Ltd shares fell 18% last week after a profit warning and a $5 billion non-cash impairment, closing Friday at A$97.96. The company cut its 2026 revenue outlook to $15.2 billion and NPATA to $3.1 billion. Interim CEO Gordon Naylor cited delays in financial benefits from growth initiatives and revenue hits in the U.S., China, and the Middle East. The ASX cash market reopens Monday at 09:59:45 Sydney time.
May 17, 2026
CSL Limited Share Price Slides Again as $5 Billion Writedown Puts Biotech Turnaround on the Clock
····

CSL Limited Share Price Slides Again as $5 Billion Writedown Puts Biotech Turnaround on the Clock

CSL Limited shares closed at A$97.26 on Thursday, down 1.55%, extending losses after a profit downgrade and plans for US$5 billion in writedowns. The stock hit its lowest level since January 2017 earlier in the week. CSL cut its FY26 revenue outlook to US$15.2 billion and expects further pressure from U.S. immunoglobulin inventory and lower albumin prices in China.
May 14, 2026
CSL Limited’s $5 Billion Write-Down Leaves One Big Question: Is the Turnaround Still Alive?
····

CSL Limited’s $5 Billion Write-Down Leaves One Big Question: Is the Turnaround Still Alive?

CSL Limited warned of about US$5 billion in new non-cash impairments and cut its FY26 outlook, sending shares down 16% Monday to their lowest since January 2017 before rebounding slightly. The company now expects FY26 revenue of US$15.2 billion and NPATA of US$3.1 billion. Impairments will be booked across FY26 and FY27, mainly tied to the Vifor acquisition and under-used assets.
May 13, 2026
UK & AU Stock Market Today: Live Updates 13.05.2026
··

UK & AU Stock Market Today: Live Updates 13.05.2026

LIVEMarkets rolling coverageStarted: May 13, 2026, 12:00 AM EDTUpdated: May 13, 2026, 11:58 PM EDT Federal Court Rules Coles Misled Shoppers with 'Down Down' Discounts May 13, 2026, 11:58 PM EDT. The Federal Court ruled that Australian supermarket giant Coles misled customers by promoting fake "Down Down" discounts on everyday groceries. Justice Michael O'Bryan found Coles' tactic of showing inflated "was" prices for short periods before applying "discounted" prices was deceptive. The Australian Competition and Consumer Commission (ACCC) sued Coles over the practice between 2021 and 2023, arguing the promotional campaigns disguised actual price increases amid inflation. Coles argued these
May 13, 2026
CSL Limited Buyback Tops A$1 Billion After Stock Hits 2017 Low
····

CSL Limited Buyback Tops A$1 Billion After Stock Hits 2017 Low

CSL Limited repurchased 110,004 shares on April 30, bringing its total buyback to 6.35 million shares for about A$1.06 billion, according to a May 1 ASX filing. The move follows a sharp stock drop after the U.S. military ended its flu vaccine mandate. CSL reported first-half net profit after tax down 81% to US$401 million. The company began a US$1.5 billion plasma plant expansion in Illinois in March.
May 1, 2026
Australia Stock Market This Week: ASX 200’s Worst Week Since March as Oil Shock, Fortescue Selloff Bite
·········

Australia Stock Market This Week: ASX 200’s Worst Week Since March as Oil Shock, Fortescue Selloff Bite

The S&P/ASX 200 dropped 1.8% for the week, closing Friday at 8,786.50, its sharpest decline since mid-March. Cochlear plunged 40.7% after slashing its profit outlook, while CSL hit a multi-year low following the end of a U.S. military vaccine mandate. Miners also fell, offsetting gains in energy stocks driven by Middle East tensions.
April 25, 2026
CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares
····

CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares

CSL’s Seqirus unit has secured a Canadian government contract to supply up to 15 million pandemic flu vaccine doses from its Tullamarine plant if a pandemic is declared. The deal follows an 81% drop in CSL’s half-year profit and a leadership change. Financial terms were not disclosed. CSL has spent about A$738.8 million on share buybacks since launching its on-market program.
March 6, 2026